

Docket Number: ENP-030
Response to January 26, 2004 Action

Applicant : Or et al.
Serial No. : 09/976,219
Filed : October 12, 2001
Title : Page 2 of 6

RECEIVED
CENTRAL FAX CENTER

MAR 30 2004

AMENDMENTS TO THE CLAIMS: THIS LISTING OF CLAIMS REPLACES ALL PRIOR VERSIONS AND THOSE CLAIMS LISTED IN THE APPLICATION AS FILED.

Claims 1-11 (Cancelled)

OFFICIAL

12. (Currently Amended) A method for treating autoimmune diseases in a subject, which comprises the step of administering to said subject a therapeutically effective amount of at least one cyclosporin analog of formula I as claimed in Claim 15.
13. (Original) The method of Claim 12, wherein said autoimmune disease is selected from conical cornea, keratitis, dysophia epithelialis cornea, leukoma, Mooren's ulcer, scleritis and Grave's ophthalmopathy.
14. (Currently Amended) A method for preventing organ transplantation rejection in a subject, which comprises the step of administering to said subject a therapeutically effective amount of at least one cyclosporin analog of formula I as claimed in Claim 15.
15. (Currently Amended) A cyclosporin analog of formula I or a pro-drug or a pharmaceutically acceptable salt thereof;

A---B---Sar-MeLeu-Val-MeLeu-Ala---U---MeLeu-MeLeu-MeVal ---

1 2

8


(I)

wherein


(i) A is of the formula:

Docket Number: ENP-030
Response to January 26, 2004 Action

Applicant : Or et al.
Serial No. : 09/976,219
Filed : October 12, 2001
Title : Page 3 of 6



(A1)



or

(A2)

wherein:

X is absent, $[-C_1-C_6]-C_1-C_6$ alkyl-, or $[-C_3-C_6]-C_3-C_6$ cycloalkyl-;

Y is selected from the group consisting of:

- (a) aryl substituted with one or more substituents independently selected from: $_CN$, C_3-C_6 -alkoxy, C_1-C_6 -alkoxy, C_3-C_6 -alkoxy substituted with aryl, haloalkyl, thioalkoxy, amino, alkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxy carbonyl, or carboxamide;
- (b) heteroaryl; or
- (c) substituted heteroaryl;

(ii) B is α -Abu-, -Val-, -Thr- or -Nva-; and

(iii) U is $-(D)Ala-$, $-(D)Ser-$, $-[O-(2\text{-hydroxyethyl})(D)Ser]-$, $-[O-(acyl)(D)Ser]-$ or $-[O-(2\text{-acyloxyethyl})(D)Ser]-$.

16. (Currently Amended) A cyclosporin analog of claim 15 defined by formula I, wherein X is absent and Y is phenyl substituted at the ortho position with a substituent independently selected from: $_CN$, C_3-C_6 -alkoxy, C_1-C_6 -alkoxy, C_3-C_6 -alkoxy substituted with aryl, haloalkyl, thioalkoxy, amino, alkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxy carbonyl, or carboxamide.

Docket Number: ENP-030
Response to January 26, 2004 Action

Applicant : Or et al.
Serial No. : 09/976,219
Filed : October 12, 2001
Title : Page 4 of 6

17. (Previously Amended) A cyclosporin analog according to claim 15 or a pro-drug or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

Compound of formula (I), where A=A1, X is absent and Y = (4'-CF₃)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-OMe)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-COOCH₃)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-COOCH₃)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'- Naphthalene); B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-t-butyl)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-AcO-)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-OCH₃)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3', 4'-OMe₂)Ph; B is - α Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyridine; B is - α Abu; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyrrole; B is - α Abu; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (N-methyl) Pyrrole; B is - α Abu; and U is -(D)Ala-;

Docket Number: ENP-030
Response to January 26, 2004 Action

Applicant : Or et al.
Serial No. : 09/976,219
Filed : October 12, 2001
Title : Page 5 of 6

Compound of formula (I), where A=A1, X is absent and Y = Thiophene; B is $-\alpha$ Abu; and U is $-(D)Ala-$;

Compound of formula (I), where A=A1, X is absent and Y = Oxazole; B is $-\alpha$ Abu; and U is $-(D)Ala-$;

Compound of formula (I), where A=A1, X is absent and Y = (S)Ph; B is $-\alpha$ Abu; and U is $-(D)Ala-$;

Compound of formula (I), where A=A1, X is absent and Y = (SO)Ph; B is $-\alpha$ Abu; and U is $-(D)Ala-$; and

Compound of formula (I), where A=A1, X is absent and Y = (SO₂)Ph; B is $-\alpha$ Abu; and U is $-(D)Ala-$.

Claim 18 (Cancelled)

19. (Previously Presented) A pharmaceutical composition, said composition comprising at least one cyclosporin analog of formula I as claimed in Claim 15, said cyclosporin analog being present alone or in combination with a pharmaceutically acceptable carrier or excipient.

20. (Previously Presented) A compound according to claim 15, wherein X is absent and Y is substituted heteroaryl.

21. (Previously Amended) A compound according to claim 15, wherein X is absent and Y is (2'-methyl)furan-2-yl.